These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 29528261)

  • 1. Influence of IL15 gene variations on the clinical features, treatment response and risk of developing childhood acute lymphoblastic leukemia in Latvian population.
    Rots D; Kreile M; Nikulshin S; Kovalova Z; Gailite L
    Pediatr Hematol Oncol; 2018 Feb; 35(1):37-44. PubMed ID: 29528261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of interleukin-15 polymorphism on the survival of adult patients with acute lymphoblastic leukemia in Egypt.
    Aly RM; Taalab MM; Ghazy HF
    Leuk Lymphoma; 2015 Jan; 56(1):151-6. PubMed ID: 24689757
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of germline genetic variants in RFC, IL15 and VDR genes with minimal residual disease in pediatric B-cell precursor ALL.
    Dawidowska M; Kosmalska M; Sędek Ł; Szczepankiewicz A; Twardoch M; Sonsala A; Szarzyńska-Zawadzka B; Derwich K; Lejman M; Pawelec K; Obitko-Płudowska A; Pawińska-Wąsikowska K; Kwiecińska K; Kołtan A; Dyla A; Grzeszczak W; Kowalczyk JR; Szczepański T; Ziętkiewicz E; Witt M
    Sci Rep; 2016 Jul; 6():29427. PubMed ID: 27427275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of interleukin-15 polymorphisms in adult acute lymphoblastic leukemia.
    Lin D; Liu C; Xue M; Liu R; Jiang L; Yu X; Bao G; Deng F; Yu M; Ao J; Zhou Y; Wu D; Liu H
    PLoS One; 2010 Oct; 5(10):e13626. PubMed ID: 21049047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
    Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
    J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease-based augmented therapy in childhood acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group.
    Yamaji K; Okamoto T; Yokota S; Watanabe A; Horikoshi Y; Asami K; Kikuta A; Hyakuna N; Saikawa Y; Ueyama J; Watanabe T; Okada M; Taga T; Kanegane H; Kogawa K; Chin M; Iwai A; Matsushita T; Shimomura Y; Hori T; Tsurusawa M;
    Pediatr Blood Cancer; 2010 Dec; 55(7):1287-95. PubMed ID: 20535816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
    Yeoh AE; Ariffin H; Chai EL; Kwok CS; Chan YH; Ponnudurai K; Campana D; Tan PL; Chan MY; Kham SK; Chong LA; Tan AM; Lin HP; Quah TC
    J Clin Oncol; 2012 Jul; 30(19):2384-92. PubMed ID: 22614971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Host genetic variants of ABCB1 and IL15 influence treatment outcome in paediatric acute lymphoblastic leukaemia.
    Lu Y; Kham SK; Ariffin H; Oei AM; Lin HP; Tan AM; Quah TC; Yeoh AE
    Br J Cancer; 2014 Mar; 110(6):1673-80. PubMed ID: 24434428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of outcomes by early treatment responses in childhood T-cell acute lymphoblastic leukemia: a retrospective study in China.
    Wei W; Chen X; Zou Y; Chang L; An W; Wan Y; Liu T; Yang W; Chen Y; Guo Y; Zhu X
    BMC Pediatr; 2015 Jul; 15():80. PubMed ID: 26174476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms in genes involved in the corticosteroid response and the outcome of childhood acute lymphoblastic leukemia.
    Fleury I; Primeau M; Doreau A; Costea I; Moghrabi A; Sinnett D; Krajinovic M
    Am J Pharmacogenomics; 2004; 4(5):331-41. PubMed ID: 15462611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.
    Flohr T; Schrauder A; Cazzaniga G; Panzer-Grümayer R; van der Velden V; Fischer S; Stanulla M; Basso G; Niggli FK; Schäfer BW; Sutton R; Koehler R; Zimmermann M; Valsecchi MG; Gadner H; Masera G; Schrappe M; van Dongen JJ; Biondi A; Bartram CR;
    Leukemia; 2008 Apr; 22(4):771-82. PubMed ID: 18239620
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia.
    Borst L; Wallerek S; Dalhoff K; Rasmussen KK; Wesenberg F; Wehner PS; Schmiegelow K
    Eur J Haematol; 2011 Jun; 86(6):477-83. PubMed ID: 21418106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical significance of glucocorticoid induction test in Chinese childhood acute lymphoblastic leukemia].
    Fan JJ; Chai YH; Hu SY; He HL; Zhao WL; Wang Y; Li J; Lu J; Xiao PF; Sun YN; Wang W; Cao L
    Zhonghua Er Ke Za Zhi; 2013 Jul; 51(7):523-6. PubMed ID: 24267134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detectable minimal residual disease before allogeneic hematopoietic stem cell transplantation predicts extremely poor prognosis in children with acute lymphoblastic leukemia.
    Sramkova L; Muzikova K; Fronkova E; Krejci O; Sedlacek P; Formankova R; Mejstrikova E; Stary J; Trka J
    Pediatr Blood Cancer; 2007 Jan; 48(1):93-100. PubMed ID: 16521130
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease is an important predictive factor of outcome in children with relapsed 'high-risk' acute lymphoblastic leukemia.
    Paganin M; Zecca M; Fabbri G; Polato K; Biondi A; Rizzari C; Locatelli F; Basso G
    Leukemia; 2008 Dec; 22(12):2193-200. PubMed ID: 18754029
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
    Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
    Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Recent advance in treatment of childhood acute lymphoblastic leukemia].
    Watanabe A
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):150-5. PubMed ID: 17301519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol.
    Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G
    Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Preliminary results of the use of MRD test among children with acute lymphoblastic leukaemia].
    Raciborska A; Wypych A; Rokicka-Milewska R; Siedlecki JA; Kulik J
    Przegl Lek; 2004; 61 Suppl 2():62-6. PubMed ID: 15686049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.